NeuroMab™ Anti-EGFR BBB Shuttle Antibody,Clone NR3059P

Figure 1 shows flow cytometry of DNA in nuclei obtained from HN5 cells after four days of in vitro incubation in DMEM-2%FCS alone or in DMEM-2%Fr containing anti-EGFR mAb (156nM) or EGF (10nM) analyze.

Figure 1 shows the DNA histogram

Figure 2 shows flow cytometry of DNA in nuclei obtained from HN5 cells after four days of in vitro incubation in DMEM-2%FCS alone or in DMEM-2%Fr containing anti-EGFR mAb (156nM) or EGF (10nM) analyze.

Figure 2 shows the percentage of cells at each stage.

Figure 3 shows the effect of antibodies directed against EGFR or its Fab fragments on the binding of I 25 -EGF to human bladder cancer cell line EJ.

Figure 4 shows the effect of antibodies directed against EGFR or its Fab fragments on the binding of 25 I-TGFo to human bladder cancer cell line EJ.

Figure 5 shows Scatchard plots of I-EGF binding to EJ cells in the absence or presence of monovalent and bivalent mAb ICR9.

Figure 6 shows Scatchard plots of I-EGF binding to EJ cells in the absence or presence of monovalent and bivalent mAb ICR62.

Figure 7 shows the effect of treatment with antibodies against EGFR or its Fab fragments on the growth of HN6 cells in vitro (the picture shows other head and neck cancer cell lines overexpressing the EGF receptor.

Figure 8 shows the effect of treatment with antibodies against EGFR or its Fab fragments on the growth of HN6 cells in vitro (Figure 8 Other head and neck cancer cell lines overexpressing EGF receptors (Figure and TGFa-induced proliferation of quiescent human foreskin fibroblasts) 9).

Figure 9 shows the effect of treatment with antibodies against EGFR or its Fab fragments on the growth of HN6 cells in vitro (Figure 9).

Figure 10 shows titration curves showing inhibition of 125I-EGF binding to EJ cells by sera taken at the indicated times. A, patient 8 (20 mg); B, patient 10 (40 mg); or C, patient 13 (100 mg).

Figure 11 shows the development of human anti-rat antibodies in serum of patient No. 9 after injection of 20 mg ICR62, as shown by binding of intact ICR62 Fab ICR62 and scFv ICR62.

Figure 12. Development of human anti-rat antibodies in serum of patient No. 11 following injection of ICR62 shown to bind intact ICR62 Fab ICR62 but not scFv ICR62 Sequence listing shows DNA and deduced amino acid sequence of ICR62 variable region Replication of ICR62 and ICR64 Chain and light chain, CDRs are shown in square brackets.